NCT00926107TerminatedPhase 2
Study of the mTOR Inhibitor Temsirolimus(CCI-779) in Patients With CA125 Only Relapse of Ovarian Cancer. A Phase II Study by the Hellenic Cooperative Oncology Group.
Hellenic Cooperative Oncology Group23 sites in 1 country9 target enrollmentStarted: June 1, 2009Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Terminated
- Sponsor
- Enrollment
- 9
- Locations
- 23
- Primary Endpoint
- Clinical progression free survival.
Study Overview
Brief Summary
The primary objective of this study is to determine the efficacy of Temsirolimus in patients with ovarian cancer with CA125 only relapse after first-line platinum-based chemotherapy.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Histologic proof of epithelial ovarian,fallopian or peritoneal carcinoma of the following histological types:serous, endometrioid, mucinous, clear cell, low differentiation.
- •Age 18 years or older
- •Patients should have received first-line platinum based chemotherapy
- •Documented CA125 progression according to GCIC criteria.
- •No evidence of measurable or evaluable disease.
- •Provision of written informed consent
- •ECOG PS 0-2
- •Life expectancy of greater than 12 weeks
- •WBC>4000/μl, platelets > 100,000/μl and a hemoglobin level > 9.5 g/dl. Adequate baseline hepatic function, defined as a total bilirubin level < 2 mg/dl, SGPT and SGOT < 2.5 times the upper limits of normal. Creatinine < 1.5 mg/dl or creatinine clearance > 60 ml/min.
- •All females of childbearing potential must have a negative serum or urine pregnancy test obtained within 2 days prior to initiation of treatment and use effective contraception during the period of therapy.
- •At least one month from the last chemotherapy administration.
- •Provision of adequate paraffin-embedded tumor tissue for translational studies (optional).
Exclusion Criteria
- •Other histological types (germ cell, granulose tumors etc)
- •History of atrial or ventricular arrhythmias and/or history of congestive heart failure, even if medically controlled. History of clinical and electrocardiographically documented myocardial infarction within the last 6 months from study entry
- •Any evidence of clinically active interstitial lung disease (patients with chronic stable radiographic changes who are asymptomatic need not be excluded)
- •Pre-existing motor or sensory neurotoxicity grade 2 according to the WHO criteria (intolerable paresthesia and/or marked motor loss or worse)
- •History of any treatment for CA125 relapse
- •Known, severe hypersensitivity to temsirolimus or any of the excipients of this product
- •Other coexisting malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ
- •Any unresolved chronic toxicity greater than CTC grade 2 from previous anticancer therapy
- •As judged by the investigator, any evidence of severe or uncontrolled systemic disease (eg unstable or uncompensated respiratory, cardiac, hepatic or renal disease)
- •Alanine amino transferase (ALT) or aspartate amino transferase (AST) greater than 2.5 times the ULRR.
- •Active infection or evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the trial/ receive protocol treatment
- •Concomitant use of Cyp3 A inducers (phenytoin, carbamazepine, rifampicin, barbiturates or St John's Wort) should be avoided and as should treatment with strong CyP 3A inhibitors
- •Treatment with a non-approved or investigational drug within 30 days before Day 1 of trial treatment.
Outcomes
Primary Outcomes
Clinical progression free survival.
Time Frame: 6-month
Secondary Outcomes
- Progression Free Survival (PFS),Survival, CA125 response rate, Safety(Duration of the study)
Investigators
Study Sites (23)
Loading locations...
Similar Trials
Terminated
Phase 1
Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer PatientsAdvanced CancersNCT00877773M.D. Anderson Cancer Center44
Active, not recruiting
Not Applicable
STUDY OF THE mTOR INHIBITOR TEMSIROLIMUS (CCI-779) IN PATIENTS WITH CA125 ONLY RELAPSE OF OVARIAN CANCERA phase II study by the Hellenic Cooperative Oncology GroupOvarian cancerEUCTR2008-007925-38-GRHellenic Cooperative Oncology Group38
Terminated
Phase 2
Pilot Study of mTOR Inhibitor Therapy in Peutz-Jeghers SyndromePeutz-Jeghers SyndromeNCT00811590University of Utah3
Terminated
Phase 2
Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell CarcinomaSquamous Cell CarcinomaNCT01009203New Mexico Cancer Care Alliance13
Completed
Not Applicable
INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With TemsirolimusCarcinoma, Renal CellLymphoma, Mantle-CellNCT01367457Pfizer243